LoadingLoadingLoading50 funds hold it.Insiders net selling.
Net selling: insiders sold $456K and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $19K to $159K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 13, 2026
Financial period
Q3 2026
Earnings per share
$4.14 expected
Revenue
$111.49B expected
Estimates as of Nov 2, 2026
EPS expected
$2.05 to $2.62
Revenue expected
18 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 13, 2026 | $4.69est. $4.14 | +13.26%beat | $112.70Best. $111.49B+1.09% | -0.4%from $113.16B |
| Jun 30, 2026Reported Jul 16, 2026 | $6.38est. $4.92 | +29.80%beat | $112.03BSEC filing | +0.4%from $111.62B |
| Mar 31, 2026Reported Apr 21, 2026 | $7.23est. $6.60 | +9.52%beat | $111.72BSEC filing | +2.0%from $109.58B |
| Dec 31, 2025Reported Jan 27, 2026 | $2.11est. $2.11 | +0.19%in line | $113.22BAlpha Vantage | +12.3%from $100.81B |
| Sep 30, 2025Reported Oct 28, 2025 | $2.92est. $2.81 | +3.91%beat | $113.16BSEC filing | +12.2%from $100.82B |
| Jun 30, 2025Reported Jul 29, 2025 | $4.08est. $4.45 | -8.31%miss | $111.62BSEC filing | +12.9%from $98.86B |
| Mar 31, 2025Reported Apr 17, 2025 | $7.20est. $7.29 | -1.23%miss | $109.58BSEC filing | +9.8%from $99.80B |
| Dec 31, 2024Reported Jan 16, 2025 | $6.81est. $6.74 | +1.04%beat | $100.81BAlpha Vantage | +6.8%from $94.43B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $113.22B | $111.72B | $112.03B | $112.69B |
| Cost of what it sold | $94.72B | $86.31B | $75.36B | $90.69B |
| Gross profit | $18.49B | $25.41B | $36.67B | $22.00B |
| What it spent | ||||
| Sales and admin | $17.00B | $15.39B | — | — |
| Other operating costs | $1.12B | $1.03B | $28.68B | $15.44B |
| Total operating expenses | $18.11B | $16.42B | $28.68B | $15.44B |
| What was left | ||||
| Operating profit | $380.0M | $8.99B | $7.99B | $6.56B |
| Interest on debt | $974.0M | $955.0M | $962.0M | $963.0M |
| Profit before tax | -$720.0M | $7.96B | $6.97B | $5.52B |
| Tax | -$938.0M | $1.48B | $1.30B | $1.22B |
| Net profit | $10.0M | $6.28B | $5.48B | $4.11B |
| EBITDA | $1.37B | $10.09B | $8.97B | $7.56B |
This stock is trending upward.
Trend
Constructive
65 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
The Zacks Analyst Blog Highlights Archer-Daniels-Midland, Freeport-McMoRan, UnitedHealth, Casey's General Stores and Crane
BullishNov 6General Mills May Sell Häagen-Dazs. Big Food Is Quitting Ice Cream
Leans bearishNov 6The Zacks Analyst Blog Highlights Archer-Daniels-Midland, Freeport-McMoRan, UnitedHealth, Casey's General Stores and Crane
BullishNov 6Canaccord Downgrades CVRx Inc (CVRX) to Hold
BearishNov 6Design Therapeutics (DSGN) Stock Price, Chart & Analysis
Leans bearishNov 6Alector (ALEC) Stock Price, Chart & Analysis
NeutralNov 6Creative Medical Technology Holdings (CELZ) Stock Price, Chart & Analysis
NeutralNov 6Denali Therapeutics (DNLI) Stock Price, Chart & Analysis
NeutralNov 6
